news
Roche drug advances KRAS-driven lung cancer treatment
Roche's experimental drug, divarasib, showed a 50% response rate in patients with KRAS G12C-mutated non-small cell lung cancer, according to new data. This early-stage trial's results suggest a significant improvement over existing treatments like Amgen's Lumakras and Mirati's Krazati, which hover around 30% response rates. It points to a new, more potent option for a form of cancer that's historically been tough to treat.
Roche's experimental drug, divarasib, showed a 50% response rate in patients with KRAS G12C-mutated non-small cell lung cancer, according to new data. This early-stage trial's results suggest a significant improvement over existing treatments like Amgen's Lumakras and Mirati's Krazati, which hover around 30% response rates. It points to a new, more potent option for a form of cancer that's historically been tough to treat.
The architecture take
This sets a new bar for KRAS drugs—the pharma chase for a more effective cancer-killing compound just got hotter. Given how quickly these drugs are evolving, we're likely to see competitive improvements across the board, pushing the boundaries of what's possible for targeted cancer therapies.